Perceptive Advisors’s Outlook Therapeutics OTLK Stock Holding History

Perceptive Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.99M	Buy	+3,139,216	New	+$1.95M	0.07%	92
2017 Q3	–	Sell	-5,237	Closed	-$837K	–	149
2017 Q2	$837K	Sell	5,237 -2,150	-29%	-$607K	0.04%	98
2017 Q1	$3.17M	Sell	7,387 -419	-5%	-$208K	0.18%	72
2016 Q4	$3.76M	Hold	7,806	–	–	0.27%	68
2016 Q3	$5.31M	Sell	7,806 -399	-5%	-$254K	0.34%	67
2016 Q2	$4.46M	Buy	+8,205	New	+$4.89M	0.31%	62

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors's OTLK Position: Q2 2026 in Review

Perceptive Advisors opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 3,139,216 shares worth $4.99M. The stake represents 0.07% of the portfolio and ranks #92 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in OTLK as recently as Q2 2017.

Perceptive Advisors first reported a position in OTLK in Q2 2016 and has held it in 6 quarters since. The position peaked at $5.31M in Q3 2016. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Perceptive Advisors held 3,139,216 shares of Outlook Therapeutics worth $4.99M as of Q2 2026.
Outlook Therapeutics was a new Perceptive Advisors position in Q2 2026.
Outlook Therapeutics made up 0.07% of Perceptive Advisors's portfolio in Q2 2026, its #92 holding.
Perceptive Advisors first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 6 quarters since.
Perceptive Advisors's Outlook Therapeutics position peaked at $5.31M in Q3 2016.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.